Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pha-665752. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 11/20 | 0.99 |
| ▸ | PDGFRB known ✓ | P09619 | 9/20 | 0.99 |
| ▸ | MET known ✓ | P08581 | 7/20 | 0.99 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.99 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.99 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.99 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.99 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.99 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.99 |
| ▸ | JAK1 known ✓ | P23458 | 1/20 | 0.99 |
| ▸ | TYK2 known ✓ | P29597 | 1/20 | 0.99 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.99 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.99 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.99 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.99 |
| ▸ | SRC | P12931 | 6/20 | 0.99 |
| ▸ | LCK | P06239 | 4/20 | 0.99 |
| ▸ | YES1 | P07947 | 4/20 | 0.99 |
| ▸ | CDK2 | P24941 | 2/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pha-665752 SCHEMBL15639803 | 1.00 | KDR (0.99) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93656 | 0.99 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93655 | 0.99 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93657 | 0.99 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93654 | 0.99 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL29376386 | 0.99 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL140412 | 0.99 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL23691031 | 0.96 | KDR (0.94) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL143795 | 0.95 | KDR (0.93) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL147331 | 0.95 | KDR (0.91) | KDRFGFR1PDGFRBMETSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| US-11319344-B2 | Non-membrane disruptive P53 activating stapled peptides | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-05-03 | — | — | US | disclosed |
| CN-107531759-B | Non-membrane disruptive p 53-activated stapled peptides | 新加坡科技研究局 | 2021-11-16 | — | — | CN | disclosed |
| EP-3256484-B1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY SCIENCE TECH & RES (SG) | 2021-06-23 | — | — | EP | disclosed |
| US-20180030090-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | US | disclosed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | disclosed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | disclosed |
| EP-2904000-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | Agency for Science, Technology and Research (SG) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014055039-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319344-B2 | Non-membrane disruptive P53 activating stapled peptides | TP53, ANXA3, ANXA2 | KDR 4441/4885PDGFRB 3577/4885MET 2009/4885 |
| US-20180030090-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | TP53, ANXA3, ANXA2 | KDR 4328/4885PDGFRB 3458/4885MET 1841/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | KDR 3638/4885PDGFRB 3622/4885MET 2104/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | KDR 1025/4885PDGFRB 2523/4885MET 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.